WO2002024234A3 - Use of recombinant gene delivery vectors for treating or preventing diseases of the eye - Google Patents

Use of recombinant gene delivery vectors for treating or preventing diseases of the eye Download PDF

Info

Publication number
WO2002024234A3
WO2002024234A3 PCT/US2001/029480 US0129480W WO0224234A3 WO 2002024234 A3 WO2002024234 A3 WO 2002024234A3 US 0129480 W US0129480 W US 0129480W WO 0224234 A3 WO0224234 A3 WO 0224234A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye
treating
gene delivery
preventing diseases
recombinant gene
Prior art date
Application number
PCT/US2001/029480
Other languages
French (fr)
Other versions
WO2002024234A2 (en
Inventor
William C Manning Jr
Varavani J Dwarki
Katherine Rendahl
Shangzhen Zhou
Laura H Mcgee
Dana Lau
John G Flannery
Sheldon S Miller
Fei Wang
Adriana Dipolo
Original Assignee
Univ California
William C Manning Jr
Varavani J Dwarki
Katherine Rendahl
Shangzhen Zhou
Laura H Mcgee
Dana Lau
John G Flannery
Sheldon S Miller
Fei Wang
Adriana Dipolo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/665,493 external-priority patent/US6943153B1/en
Application filed by Univ California, William C Manning Jr, Varavani J Dwarki, Katherine Rendahl, Shangzhen Zhou, Laura H Mcgee, Dana Lau, John G Flannery, Sheldon S Miller, Fei Wang, Adriana Dipolo filed Critical Univ California
Priority to AU2001292881A priority Critical patent/AU2001292881A1/en
Publication of WO2002024234A2 publication Critical patent/WO2002024234A2/en
Publication of WO2002024234A3 publication Critical patent/WO2002024234A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function

Abstract

Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.
PCT/US2001/029480 2000-09-20 2001-09-20 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye WO2002024234A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001292881A AU2001292881A1 (en) 2000-09-20 2001-09-20 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/665,493 US6943153B1 (en) 1999-03-15 2000-09-20 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US09/665,493 2000-09-20

Publications (2)

Publication Number Publication Date
WO2002024234A2 WO2002024234A2 (en) 2002-03-28
WO2002024234A3 true WO2002024234A3 (en) 2002-12-27

Family

ID=24670335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029480 WO2002024234A2 (en) 2000-09-20 2001-09-20 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Country Status (2)

Country Link
AU (1) AU2001292881A1 (en)
WO (1) WO2002024234A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066780A2 (en) 1999-04-30 2000-11-09 University Of Florida Adeno-associated virus-delivered ribozyme compositions and methods of use
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US7056885B1 (en) 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
US7291483B2 (en) 1999-07-27 2007-11-06 Curagen Corporation FGF-CX polynucleotide sequences and methods of producing same
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
EP1401855A4 (en) * 2001-06-15 2004-12-22 Curagen Corp Novel fibroblast growth factor and nucleic acids encoding same
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
WO2004027019A2 (en) 2002-05-01 2004-04-01 University Of Florida Research Foundation, Inc. Improved raav expression systems for genetic modification of specific capsid proteins
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AU2003297607A1 (en) * 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2006031689A2 (en) 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
US20090131313A1 (en) * 2005-06-17 2009-05-21 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods for treating or preventing tissue deterioration, injury or damage
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
ES2329636B2 (en) 2006-02-17 2010-07-26 Universitat De Valencia, Estudi General (Participa Con El 70%) USE OF PEDF FACTOR TO INDUCE MOTHER CELLS SELF-RENEWAL
WO2012007458A1 (en) 2010-07-12 2012-01-19 Universidad Autónoma De Barcelona Gene therapy composition for use in diabetes treatment
DK2601214T3 (en) 2010-08-06 2018-02-05 Genzyme Corp VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
CN104468061B (en) * 2014-11-25 2019-08-20 厦门雅迅网络股份有限公司 A kind of method and system of real-time reliable data transmission under low-speed network environment
EP3978614A3 (en) 2015-01-07 2022-07-27 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
CN106591370A (en) * 2015-10-19 2017-04-26 南京华贞生物医药科技有限公司 Virus vector for treating autoimmune related diseases and diabetes, construction method and applications thereof
CN110268052A (en) * 2016-12-22 2019-09-20 蓝天疫苗有限责任公司 The method of purified virus
RU2019142845A (en) * 2017-05-24 2021-06-24 Университат Аутонома Де Барселона VIRAL EXPRESSION STRUCTURE CONTAINING THE CODING SEQUENCE OF FIBROBLAST GROWTH FACTOR 21 (FGF21)
IL270882B2 (en) * 2017-05-24 2024-02-01 Univ Barcelona Autonoma Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
KR102205830B1 (en) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 Pharmaceutical Composition for Treating Macular Degeneration Containing AAV Including cDNA of Soluble VEGFR Variant

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013071A1 (en) * 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
WO1999036511A2 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
WO1999066959A2 (en) * 1998-06-01 1999-12-29 Selective Genetics, Inc. Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival
WO2000015822A1 (en) * 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
WO2000054813A2 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2000071582A1 (en) * 1999-05-20 2000-11-30 Human Genome Sciences, Inc. Fibroblast growth factor 14

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013071A1 (en) * 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
WO1999036511A2 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
WO1999066959A2 (en) * 1998-06-01 1999-12-29 Selective Genetics, Inc. Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival
WO2000015822A1 (en) * 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
WO2000054813A2 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2000071582A1 (en) * 1999-05-20 2000-11-30 Human Genome Sciences, Inc. Fibroblast growth factor 14

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKIMOTO M ET AL: "ADENOVIRALLY EXPRESSED BASIC FIBROBLAST GROWTH FACTOR RESCUES PHOTORECEPTOR CELLS IN RCS RATS", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND, US, vol. 40, no. 2, 1999, pages 273 - 279, XP000917329, ISSN: 0146-0404 *
CAYOUETTE M ET AL: "ADENOVIRUS-MEDIATED GENE TRANSFER OF CILIARY NEUROTROPHIC FACTOR CAN PREVENT PHOTORECEPTOR DEGENERATION IN THE RETINAL DEGENERATION (RD) MOUSE", HUMAN GENE THERAPY, vol. 8, no. 4, 1 March 1997 (1997-03-01), pages 423 - 430, XP000876513, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
AU2001292881A1 (en) 2002-04-02
WO2002024234A2 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
CZ63995A3 (en) Virus vectors and their use in gene therapy
WO2002053703A3 (en) Aav2 vectors and methods
WO2002069900A3 (en) Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
WO2001083729A3 (en) Vectors for ocular transduction and use thereof for genetic therapy
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
WO2002072780A3 (en) Igf antagonist peptides
EP1381280A4 (en) Viral vectors and their use in therapeutic methods
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2002024640A3 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
WO2006058231A3 (en) Viral vectors
WO1998013500A3 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO2003048205A3 (en) Novel proteins with il-6 inhibiting activity
WO2001014417A3 (en) Pesticidal proteins
MXPA03010684A (en) Peptides and the use thereof in darkening the skin.
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
WO2003018606A3 (en) Casein derived peptides and uses thereof in therapy
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.
EP1319080A4 (en) Plasmid originated from bifidobacterium, recombinant expression vector using the plasmid and transformation method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP